Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities

NCT04410302 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT04410302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04410302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities
Lead sponsor
University of California, Davis
Phase
Observational
Overall status
Recruiting
Start date
November 12, 2019
Completion date
June 30, 2027
Enrollment
500 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma, gastric carcinoma, liver and intrahepatic bile duct carcinoma, lung carcinoma, malignant neoplasm